| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4a7ac31dafa9b644bcbf73f79c4695dc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2531-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2561-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-686 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate |
2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e407298df0050f3d1ba569c872a2518b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0767cda20d8f3ccc28636fdf07b625b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_577eb4f73e6605304c9324db511faa1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e0ab0dfc702c3a8cd17e15208d779ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d837eb2e82d29aed7ff74bae2228fe5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48a84d7a782ebdbad58b69f93a469e67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ccb5a532d8ecc84336a47b4f1d9e4ab |
| publicationDate |
2021-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021085669-A1 |
| titleOfInvention |
Treating patients harboring an isocitrate dehydrogenase 1 (idh-1) mutation |
| abstract |
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11376246-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11311527-B2 |
| priorityDate |
2018-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |